Intravenous administration could become a delivery route of choice for prophylactic and curative gene therapies on condition that genes cross the capillary barrier and reach target tissues without being degraded. We investigated the kinetics and process of transgene delivery through mouse lung capillaries following DNA complexation with linear polyethylenimine (L-PEI) and intravenous injection. Using digoxin-labeled DNA we followed the cellular localization of DNA at different times after injection and correlated these findings with cell markers and transgene expression. At 2 h after injection some DNA was still localized on the interior of the capillary lumen, but other complexes had already crossed the barrier and resulted in gene expression. At 24 h after injection most
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The systemic route could provide a relatively non-invasive means of gene delivery to the lung for a number of prophylactic and therapeutic situations. For instance, expression in pneumocytes of a dominant FHIT (fragile histidine triad) gene has been suggested for prophylaxis of certain forms of lung cancer [1] [2] [3] and intravenous delivery of therapeutic genes is a realistic alternative to aerosol or intratracheal injections for cystic fibrosis (CF) therapy. Indeed, in CF patients with established lung disease the lung epithelium can become inaccessible for vector-DNA complexes because of thick mucus accumulation, rendering the intravenous route more attractive, on condition that genes reach the appropriate cellular sites. 4 A series of recent studies have shown the lung capillaries to be a privileged site for transgene expression following intravenous gene delivery with various nonviral vectors. [5] [6] [7] We too have shown that a synthetic cationic polymer, 22 kDa linear polyethylenimine (L-PEI or ExGen 500; Euromedex, Souffleweyersheim, France), provides particularly high levels of transgene expression in the mouse lung. 8 However, with L-PEI, the detection of ␤-galactosidase activity in lung sections seemed to indicate that the transgene was expressed in pneumocytes beyond the endothelium barrier. This observation, which labeled DNA was localised in pulmonary cells, as was transgene expression. Only rarely was transgene expression found in endothelial cells, suggesting that the complexes cross the capillary barrier rapidly. Levels of caspase-1-like activity did not increase following transfection implying that L-PEI/DNA complexes are transported across cellular barriers by a non-damaging, physiological process, without causing inflammation. The high levels of expression of different transgenes in pneumocytes indicates that transport of L-PEI/DNA complexes through the endothelial barrier does not affect their transfection capacity. These findings open up new possibilities for gene delivery and its application to the lung. Gene Therapy (2000) 7, 499-504.
required confirmation by the use of cell markers to identify unambiguously the cell types, raised a key question. If the genes were reaching cells beyond the endothelium, how is this cell barrier crossed? Two main hypotheses can be proposed: either rupture of the intracellular junctions or a cell permeation mechanism such as transcytosis. 9 Here we set out, first, to confirm that passage of the endothelium barrier does occur. To this end we used double immunocytochemistry to identify the cell types and to co-localize them with digoxin-labeled DNA or transgene expression. Next, we analyzed the kinetics and the cellular basis of endothelium crossing.
In a first series of experiments we assayed luciferase expression in lungs and livers of animals injected with either L-PEI/DNA complexes or naked DNA at timepoints between 2 h and 72 h. As shown in Figure 1a and b, luciferase expression was detected in both liver and lung within 2 h of injection at two to three levels of magnitude higher than in uninjected animals. In the lung, expression at 2 h was over 10 5 RLU/mg protein and then peaked close to 10 7 RLU/mg protein at 6 and 12 h postinjection (p.i.), two orders of magnitude higher than in liver at the same time-points. In contrast, in control animals that had received naked DNA, expression levels did not exceed background values in the liver, and only reached 10 3 RLU/mg protein in the lung between 2 and 12 h p.i. Thus, L-PEI vectorization strongly favored transfection of lung tissue in both the short and longer term.
The remarkably rapid and efficient transgene expression in the lung raised the question of the cellular localization of the DNA at the earliest time-point and whether DNA localization could be correlated with gene expression. The cellular localization of vectorized DNA was assessed by injecting digoxin-labeled DNA and then examining sections from injected animals with an antibody against digoxin and using specific markers for different cell types. Antibodies against factor VIII (Dako, Glostrup, Denmark) and surfactant protein A 4 were used to identify endothelial and pulmonary cells, respectively. As shown in Figure 2a -d, at 2 h p.i. labeled complexes were found in the lumen of small capillaries (Figure 2a) , within the endothelial cell layer (arrowheads in Figure  2b , c), in pulmonary cells (arrow in Figure 2b ) and in cells located in close proximity of blood vessels (arrows in Figure 2c ). This latter localization correlated with ␤-galctosidase expression already seen at 2 h p.i. in groups of pulmonary cells adjacent to blood vessels (Figure 2d) .
At 24 h after intravenous injection digoxin-labeled DNA was found in the space between blood vessels and bronchioli and in endothelial and respiratory cells ( Figure  2e ). The identity of endothelial ( Figure 2f ) and pulmonary cells (Figure 2g , h) was confirmed by immunocytochemistry with appropriate markers. DNA localization was well correlated with sites of transgene expression. Indeed, when digoxin-labeled DNA was coinjected with a CMV-LacZ reporter construct, ␤-galactosidase activity was detected in the same sites where labeled DNA was present. In particular, reporter gene expression was present in large groups of cells located between major blood vessels and bronchioles (Figure 3a) . High power examination of the same sections immunostained with the appropriate markers (Figure 3b, c) revealed that ␤-galactosidase expression was present both in endothelial cells and in pneumocytes.
These observations raised the question of the cellular mechanism underlying the rapid translocation of complexes through the endothelium. One possibility could be rupture of the endothelium cell junctions. Such an event would most likely be followed by necrosis and inflammation. We measured a biochemical indicator of inflammation: caspase 1-like activity. 10, 11 No increased caspase 1-like activity was detected in lungs at any timepoint p.i. irrespective of whether animals were injected with L-PEI and a luciferase expressing plasmid ( Figure  4a ) or with L-PEI and an empty plasmid (Figure 4b) . Similarly, injection of L-PEI alone, uncomplexed to DNA, did not cause capsase 1 activation at any time-point, in fact levels in treated animals were lower than in controls (Figure 4c) .
A final point we addressed was the cause of the rapid loss of expression between 24 and 48 h. We used semiquantitative PCR to assay luciferase plasmid present in lung extracts at given time points p.i. As shown in Figure 5 , pCMV-luc expression in lung at 48 h p.i. is less intense than at 2 and 6 h p.i. Quantification by densitometry and normalization against those for endogenous ␤-actin amplified from the same samples, showed the ratio of luc/actin to be less than 0.2 at 48 h as compared with ratios of 0.4 to 0.75 at earlier time-points.
To determine whether plasmid loss was associated with apoptosis, we measured caspase 3 (CPP32)-like activity in tissues. Even though caspase 3-like activity in injected lungs was increased slightly (two-fold), and significantly, at 12 and 48 h p.i. but not at 2, 6 and 24 h, the values observed were always an order of magnitude less than those in the liver at the same time ( Figure 6 ). These low levels of caspase 3-like activity in the L-PEI-transfected lung suggest that plasmid loss is unlikely to be due to apoptosis. Indeed, we co-transfected CMV-luc with a plasmid expressing the anti-apoptotic gene bclX L 12,13 and found no increase in duration of reporter gene expression in the lung (data not shown).
In this study, we analyzed the kinetics and process of L-PEI-based gene delivery to the mouse lung. The findings bolster our postulate that L-PEI/DNA complexes can pass the capillary barrier in the lung, so as to reach and transfect other pulmonary cells types. Three series of observations corroborate the hypothesis that transcytosis 
major blood vessels (arrow). DNA can be detected in endothelial cells of blood vessels (arrowheads in b, c) and in the alveolar cells in close proximity to the vessels (arrows in b and c). Two hours after injection with a LacZ reporter construct, some alveolar cells already express ␤-galactosidase (d). At 24 h p.i. DNA was no longer found in the lumen of blood vessels but could be detected between blood vessels and bronchioli (e; arrows in f, g) and in groups of cells in the alveolar region (arrows in h). DNA distribution at 24 h is recapitulated by the expression of LacZ observed at the same time after injection (see Figure 3). Digoxin labeling was carried out according to the manufacturer's instructions (Panvera, Madison, WI, USA). Briefly, 50 g of DNA was mixed with the labeling buffer, dye added and incubated at 37°C for 1 h. Ethanol/NaCl precipitation was carried to separate labeled from non-labeled DNA. Labeling was verified by dot blotting, and did not modify the L-PEIbased transfection activity of DNA (data not shown). Digoxin-labeled DNA was injected in a 1:9 (w/w) mix with unlabeled DNA and was revealed with an alkaline-phosphatase-coupled anti-digoxigenin antibody followed by NBT/BCIP solution according to the manufacturer's instructions (Boehringer-Roche, Mannheim, Germany). In sections double stained with a lung marker (either factor VIII or surfactant protein A) the reaction with the anti-digoxigenin antibody (Amersham, Les Ulis, France) was performed after completion of the peroxidase reaction. Anti-digoxigenin antibody fully cross-reacts with digoxin. as, alveolar space; bv, blood vessel; br, bronchioli. Bar: 40 m in a, b, e-h; 60 m in d; 200 m in c. Representative sections are shown. The experiment was carried out three times with a minimum of four animals per group (total of 12 lungs examined).
of complexes through the lung endothelium is occurring: first, the localization and identity of the cells expressing the transgenes, second, the rapidity of transfer and gene expression, and third, the lack of inflammatory activity.
Our primary argument is that transgene expression is found in pulmonary cells identified unambiguously by specific cell markers. Indeed, we used double immunocytochemistry and histochemistry to localize both digoxinlabeled DNA and transgene expression with respect to cellular markers identifying either endothelial cells (antifactor VIII) or surfactant-expressing pulmonary cells (anti-surfactant protein A). Various combinations of markers showed that plasmid DNA vectorized with L-PEI is found in the alveolar cells as early as 2 h p.i. and in these Gene Therapy same cells as well as pulmonary cells at the base of the bronchioles at 24 h p.i. Localization of digoxin-labeled DNA in these cell types was correlated with transgene expression. Transgene expression was found in endothelial cells, but this was by no means the major site of expression.
The passage of the endothelium is extremely rapid, as one would expect for a transcytotic mechanism; labeled DNA and transgene expression being found in the alveolar cells as early as 2 h p.i. Both luciferase activity and ␤-gal transgenes showed significant levels of activity at the earliest time-point examined. This means that within 2 h, not only have the complexes moved through the endothelial cells but that they have re-entered the Gene Therapy a b c Figure 2 ; in all cases nuclei were identified by nuclear fast red counterstaining. pulmonary cells, undergone trafficking to the nucleus and produced functional protein.
Figure 3 LacZ expression in the lung 24 h after intravenous injection. Mice were injected with a plasmid (125 g) containing the coding sequence of ␤-galactosidase (LacZ) under the CMV promoter (Vical, San Diego, CA, USA). Mice were killed 2 h and 24 h after injection, sequentially perfused with 5 mg/l heparin in saline, 2% paraformaldehyde, saline and a standard ␤-galactosidase revealing solution (0.8 mg/ml X-gal, Boehringher-Roche). After perfusion, the lungs were dissected and the ␤-galactosidase reaction continued for 48 h by immersion in the X-gal solution at 30°C. After staining, the lungs were embedded in paraffin and sectioned (5 m). The sections were subsequently immuno-stained either with anti-factor VIII (a, b) or with anti-surfactant protein A (c) antibodies as in

␤-Galactosidase activity is prominent in groups of cells located in close proximity to major blood vessels (arrowheads in a). At higher magnification it is clear that both respiratory endothelial cells (immunostained by the anti-factor VIII antibody; arrows in b) and type II pneumocytes (immunostained by the anti-surfactant protein
Our final argument in favor of a transcytotic mechanism is the lack of inflammation resulting from L-PEI/DNA gene transfer. If transport is not occurring by a cell based-transfer mechanism, then passage across the endothelium would involve rupture of the tight intercellular junctions. Indeed, one could suppose that injection of a large volume (up to 20% of blood volume) such as used here, could cause a surge in blood pressure and rupture of the endothelium cell junctions. This would be followed by cell damage, necrotic cell death and inflammation associated with a caspase 1 increase. Previous histological evidence 8 has suggested the innocuous nature of this vectorization method, and tends to rule out the rupture theory. These biochemical results showing no increase in caspase 1-like activity in the lung reinforce the idea that passage occurs through a physiological transport process, such as transcytosis. 
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Transgene expression occurring in the pulmonary cells appears to be favored over expression in the endothelial cells themselves. This seems to be a hallmark characteristic of gene delivery to the lung with L-PEI, and is not seen, at least not at the high level reported here, with other cationic vectors. Indeed, although some authors have reported the presence of either plasmid 4 or limited gene expression in pulmonary cells 14 following delivery with cationic lipids, the majority of the signal is found in endothelial cells.
Two key factors can be proposed to explain the particularly high levels of transgene expression in pulmonary cells following transfection with L-PEI: the method used for formulation of complexes and the inherent buffering capacity of L-PEI. We formulated DNA/L-PEI complexes in a non-ionic solution (5% glucose) that results in the formation of stable particles of 30-60 nm diameter. 15 These particles seem to be remarkably stable in physiological fluids. 15 The endosomal buffering capacity of PEI, [16] [17] [18] could well explain the fact that PEI/DNA complexes can survive the passage through the endosome/transcytotic pathway. In PEI, one in every third atom is an amino nitrogen that can be protonated, making PEI the cationic polymer having the highest charge density potential known. The protonation level of PEI increases from 20 to 45% between pH 7 and 5, 19 thus increasing its buffering capacity as endosomal pH decreases. Another enhancing factor is probably the high level of transcytosis that occurs in the lung. 20 Moreover, although, this transcytotic delivery of PEI/complexes across the capillary barrier appears particularly favorable in the lung, the fact that PEI is an excellent vector for conjugating cell-specific ligands [21] [22] [23] [24] means the approach could be adapted to other target tissues, for both prophylactic and curative procedures.
A final point is that plasmid loss in the lung has no obvious correlation with increased apoptosis. Even in the liver where caspase 3-like activity was increased, levels were only one order of magnitude over controls. A possible explanation of the plasmid loss in the lungs is that a mitotic population of cells is being transfected, and that during mitosis plasmid is diluted and degraded.
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